Literature DB >> 23015360

Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.

David P Steensma1.   

Abstract

Just as a pawnshop owner who is unable to distinguish a genuine Rolex™ watch from a cheap knockoff courts financial ruin, the physician who fails to discriminate between authentic myelodysplastic syndromes (MDS) and conditions resembling MDS risks misinforming or harming patients. This review summarizes minimal criteria for diagnosing MDS and discusses common diagnostic challenges. MDS needs to be separated from numerous neoplastic and non-clonal hematologic disorders that can mimic MDS, including other myeloid neoplasms, nutritional deficiencies, toxin exposures, aplastic anemia, and inherited disorders (e.g., congenital sideroblastic anemia). Some distinctions are more critical therapeutically than others; e.g., recognizing B12 deficiency is more important than parsing high-risk MDS from erythroleukemia. Diagnostically ambiguous cases may be assigned holding-pattern terms, "idiopathic cytopenia(s) of undetermined significance" (ICUS) or "idiopathic dysplasia of undetermined significance" (IDUS), while awaiting clarifying information or further clinical developments. In the future, advances in molecular pathology will improve diagnostic accuracy, especially in morphologically non-descript cases.

Entities:  

Mesh:

Year:  2012        PMID: 23015360     DOI: 10.1007/s11899-012-0140-3

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  83 in total

1.  Spurious elevations of vitamin B12 with pernicious anemia.

Authors:  David T Yang; Rachel J Cook
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

2.  Pyrazinamide-induced sideroblastic anemia.

Authors:  Giuseppe Colucci; Tobias Silzle; Max Solenthaler
Journal:  Am J Hematol       Date:  2011-08-04       Impact factor: 10.047

3.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

4.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

5.  Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.

Authors:  Jakob R Passweg; Aristoteles A N Giagounidis; Mathew Simcock; Carlo Aul; Christiane Dobbelstein; Michael Stadler; Gert Ossenkoppele; Wolf-Karsten Hofmann; Kristina Schilling; André Tichelli; Arnold Ganser
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

6.  HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.

Authors:  Yogen Saunthararajah; Ryotaro Nakamura; Jun-Mo Nam; Jamie Robyn; Fausto Loberiza; Jaroslaw P Maciejewski; Toni Simonis; Jeffrey Molldrem; Neal S Young; A John Barrett
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

Review 7.  Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions.

Authors:  P Valent; H-P Horny
Journal:  Eur J Clin Invest       Date:  2009-05-06       Impact factor: 4.686

Review 8.  Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes.

Authors:  J I Dickstein; J W Vardiman
Journal:  Am J Clin Pathol       Date:  1993-04       Impact factor: 2.493

9.  Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.

Authors:  Arjan A van de Loosdrecht; Canan Alhan; Marie Christine Béné; Matteo G Della Porta; Angelika M Dräger; Jean Feuillard; Patricia Font; Ulrich Germing; Detlef Haase; Christa H Homburg; Robin Ireland; Joop H Jansen; Wolfgang Kern; Luca Malcovati; Jeroen G Te Marvelde; Ghulam J Mufti; Kiyoyuki Ogata; Alberto Orfao; Gert J Ossenkoppele; Anna Porwit; Frank W Preijers; Stephen J Richards; Gerrit Jan Schuurhuis; Dolores Subirá; Peter Valent; Vincent H J van der Velden; Paresh Vyas; August H Westra; Theo M de Witte; Denise A Wells; Michael R Loken; Theresia M Westers
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

Review 10.  The hematological complications of alcoholism.

Authors:  H S Ballard
Journal:  Alcohol Health Res World       Date:  1997
View more
  26 in total

1.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Authors:  David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert
Journal:  Blood       Date:  2015-04-30       Impact factor: 22.113

Review 2.  The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS).

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

3.  Next-Generation Gene Sequencing Differentiates Hypoplastic Myelodysplastic Syndrome from Aplastic Anemia.

Authors:  Jeffrey L Lew; Joshua L Fenderson; Mark G Carmichael
Journal:  Hawaii J Med Public Health       Date:  2017-11

Review 4.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Authors:  Aaron C Shaver; Adam C Seegmiller
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

5.  Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia.

Authors:  Elizabeth A Morgan; Mark N Lee; Daniel J DeAngelo; David P Steensma; Richard M Stone; Frank C Kuo; Jon C Aster; Christopher J Gibson; R Coleman Lindsley
Journal:  Blood Adv       Date:  2017-09-13

6.  What should I know before ordering a bone marrow aspiration/biopsy in patients with vitamin B12 deficiency?

Authors:  Jaskirat Randhawa; Sarah L Ondrejka; Sebouh Setrakian; Harris Taylor
Journal:  BMJ Case Rep       Date:  2013-07-08

Review 7.  A primary care approach to myelodysplastic syndromes.

Authors:  Djamshed Samiev; Vijaya R Bhatt; Joel D Armitage; Lori J Maness; Mojtaba Akhtari
Journal:  Korean J Fam Med       Date:  2014-05-22

8.  MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.

Authors:  Brian Kwok; Jeff M Hall; John S Witte; Yin Xu; Prashanti Reddy; Keming Lin; Rachel Flamholz; Bashar Dabbas; Aine Yung; Jenan Al-Hafidh; Emily Balmert; Christine Vaupel; Carlos El Hader; Matthew J McGinniss; Shareef A Nahas; Julie Kines; Rafael Bejar
Journal:  Blood       Date:  2015-10-01       Impact factor: 22.113

Review 9.  [Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification].

Authors:  A H Schmitt-Graeff; M J Müller; P Fisch
Journal:  Pathologe       Date:  2013-02       Impact factor: 1.011

10.  Factors predicting early mortality after new diagnosis of myelodysplastic syndrome: A population-based study.

Authors:  Annie M Jacobsen; Jenny N Poynter; Michaela R Richardson; Phuong L Nguyen; Betsy Hirsch; Adina Cioc; Michelle A Roesler; Erica D Warlick
Journal:  Eur J Haematol       Date:  2019-05-16       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.